Dr Ziad Bakouny speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about a study looking at the integrative molecular characterisation of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).

He explains that patients with sarcomatoid and rhabdoid are still doing poorly and not responding so well to targeted therapies, however it has been suggested by studies that there could be a benefit to this population in the use of immune checkpoint inhibitors.

Dr Bakouny reports that across all the data immune checkpoint inhibitors seemed to conferring a strong benefit to patients with sarcomatoid and rhabdoid renal cell carcinoma.